Bronchial Asthma
Respiratory
1
Pipeline Programs
2
Companies
6
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
AstraZenecaCAMBRIDGE, United Kingdom
5 programsA Follow-up Programme for Patients Using Symbicort SMART in Normal Clinical PracticeN/A1 trial
A Pharmaceopidemiological Study in Patients Who Use Symbicort SMARTN/A1 trial
Fasenra Pediatric Japan Post-Marketing Study(PMS)N/A1 trial
Pulmicort Respules 0.25/0.5 Specific Clinical Experience InvestigationN/A1 trial
Pulmicort Turbuhaler 100/200 Specific Clinical Experience InvestigationN/A1 trial
Active Trials
+2 more trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
Novartisinhaled corticosteroid therapy
AstraZenecaFasenra Pediatric Japan Post-Marketing Study(PMS)
AstraZenecaPulmicort Turbuhaler 100/200 Specific Clinical Experience Investigation
AstraZenecaA Follow-up Programme for Patients Using Symbicort SMART in Normal Clinical Practice
AstraZenecaA Pharmaceopidemiological Study in Patients Who Use Symbicort SMART
AstraZenecaPulmicort Respules 0.25/0.5 Specific Clinical Experience Investigation
Clinical Trials (6)
Total enrollment: 7,137 patients across 6 trials
A Study to Assess the Efficacy of Inhaled Corticosteroid (ICS) Therapy in Moderate-Severe Bronchial Asthma
Start: Jul 200626 patients
Phase 1/2Completed
Fasenra Pediatric Japan Post-Marketing Study(PMS)
Start: Jul 2024Est. completion: Mar 202740 patients
N/ARecruiting
Pulmicort Turbuhaler 100/200 Specific Clinical Experience Investigation
Start: Sep 2010Est. completion: Sep 2015301 patients
N/ACompleted
NCT00505388AstraZenecaA Follow-up Programme for Patients Using Symbicort SMART in Normal Clinical Practice
A Follow-up Programme for Patients Using Symbicort SMART in Normal Clinical Practice
Start: Jul 2007Est. completion: Apr 20105,137 patients
N/ACompleted
A Pharmaceopidemiological Study in Patients Who Use Symbicort SMART
Start: Jun 2007Est. completion: May 20101,000 patients
N/ACompleted
Pulmicort Respules 0.25/0.5 Specific Clinical Experience Investigation
Start: Oct 2006Est. completion: Jul 2011633 patients
N/ACompleted
Related Jobs in Respiratory
Ausbildung zum Pharmakanten (m/w/d)
Ferring Pharmaceuticals
Kiel, Germany
20h ago
Global Senior Medical Director – Respiratory Pipeline Medical Lead
Pfizer
United States - New York - New York City
Yesterday
$275K - $458K/yr
Praktikant (m/w/d) Marketing Onkologie
Amgen
Germany - Munich
Yesterday
Sr Product Manager, Monarch (1 of 2)
Johnson & Johnson
Santa Clara, California, United States of America
Yesterday
$142K - $245K/yr
Laboratory Assistant (m/w/d)
Ferring Pharmaceuticals
Kiel, Germany
Yesterday
Director Quality Control (m/w/d)
Ferring Pharmaceuticals
Kiel, Germany
Yesterday
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 7,137 patients
2 companies competing in this space